Suchergebnisse - "MOLNUPIRAVIR"

Evaluation of the course of improvement with molnupiravir treatment for feline infectious peritonitis.

Alternate Title: Évaluation de l'évolution de l'amélioration de la péritonite infectieuse féline sous traitement par molnupiravir.

Autoren: Shino Yoshida Mei Sugawara-Suda Kazuyoshi Sasaoka et al.

Quelle: Canadian Veterinary Journal / Revue Vétérinaire Canadienne. May2025, Vol. 66 Issue 5, p546-554. 9p.

Schlagworte: Molnupiravir, Veterinary hospitals, Teaching hospitals, Treatment duration, Symptoms

Multi spectroscopic investigations with molecular docking and molecular dynamics simulation of the binding mechanism of molnupiravir to bovine serum albumin.

Autoren: Mansour, Fotouh R. Elhosary, Nada Elagamy, Samar H. et al.

Quelle: BMC Chemistry. 10/27/2025, Vol. 19 Issue 1, p1-12. 12p.

Schlagwörter: *MOLNUPIRAVIR, *SERUM albumin, *MOLECULAR dynamics, *ULTRAVIOLET-visible spectroscopy, *RECEPTOR-ligand complexes, *FLUORESCENCE spectroscopy, *ANTIVIRAL agents, *MOLECULAR docking

An exploratory binding study of molnupiravir efficacy against emerging Omicron SARS-CoV-2 variants.

Autoren: Ahmad, Faisal Basharat, Zarrin Janjua, Ayesha et al.

Quelle: Scientific Reports. 10/21/2025, Vol. 15 Issue 1, p1-16. 16p.

Schlagwörter: *MOLNUPIRAVIR, *SARS-CoV-2, *PROTEIN-ligand interactions, *LIGAND binding (Biochemistry), *RNA replicase, *MOLECULAR dynamics, *SARS-CoV-2 Omicron variant

Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis.

Autoren: Moghadam, Seyed Hamid Pakzad Sarkoohi, Ali Navidi, Zia et al.

Quelle: Immunity, Inflammation & Disease. Oct2025, Vol. 13 Issue 10, p1-10. 10p.

Schlagwörter: *REMDESIVIR, *MOLNUPIRAVIR, *COMPARATIVE studies, *ADVERSE health care events, *TREATMENT effectiveness, *COVID-19, *SAFETY

Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice.

Autoren: Bamunuarachchi, Gayan Zhao, Fang R. Bricker, Traci L. et al.

Quelle: Journal of Virology. Oct2025, Vol. 99 Issue 10, p1-16. 16p.

Schlagwörter: *MOLNUPIRAVIR, *ANTIVIRAL agents, *LABORATORY mice, *VIRAL replication, *IMMUNE response, *PATHOLOGY, *PATHOGENIC viruses, *TICK-borne diseases

Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model.

Autoren: Labaye, Solene Djellali, Fatima Peytavin, Gilles et al.

Quelle: Journal of Antimicrobial Chemotherapy (JAC). Oct2025, Vol. 80 Issue 10, p2807-2813. 7p.

Schlagwörter: *COVID-19, *MOLNUPIRAVIR, *MATERNAL-fetal exchange, *PREGNANCY, *COVID-19 treatment, *BIOLOGICAL models, *DRUGS, *RITONAVIR

Divergent sustainability profiles of molnupiravir synthesis routes are governed by solvent use and process design.

Autoren: Chen, Zhengyun Lian, Justin Z. Huang, Haozhou et al.

Quelle: Proceedings of the National Academy of Sciences of the United States of America. 9/23/2025, Vol. 122 Issue 38, p1-12. 12p.

Schlagwörter: *SUSTAINABILITY, *MOLNUPIRAVIR, *COST benefit analysis, *PRODUCT life cycle assessment, *ENVIRONMENTAL impact analysis, *CHEMICAL processes, *SOLVENTS, *SUSTAINABLE chemistry

Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays.

Autoren: Huntsman, Margaret Carrell Marikawa, Yusuke

Quelle: Toxicological Sciences. Sep2025, Vol. 207 Issue 1, p74-90. 17p.

Schlagwörter: *MOLNUPIRAVIR, *DEVELOPMENTAL toxicology, *COVID-19 treatment, *IN vitro studies, *PLURIPOTENT stem cells, *TOXICITY testing

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Quelle: Lancet Infectious Diseases. Sep2025, Vol. 25 Issue 9, p1000-1010. 11p.

Schlagwörter: *COVID-19, *MOLNUPIRAVIR, *HOSPITAL admission & discharge, *COVID-19 treatment, *MEDICAL research

Effectiveness of molnupiravir for the treatment of COVID-19: a systematic literature review of real-world observational studies.

Autoren: Bromfield, Samantha G. Periyasamy, Ramu Babu, Veeri Rajendra et al.

Quelle: Current Medical Research & Opinion. Aug2025, Vol. 41 Issue 8, p1417-1438. 22p.

Schlagwörter: *MOLNUPIRAVIR, *COVID-19, *TREATMENT effectiveness, *MORTALITY, *IMMUNOCOMPROMISED patients, *MEDICAL care, *ANTIVIRAL agents

Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample.

Autoren: ATEŞ, Ali Kemal¹ alikemal.ates@dicle.edu.tr

Quelle: Journal of Research in Pharmacy. 2025, Vol. 29 Issue 4, p1746-1752. 7p.

Schlagwörter: *MOLNUPIRAVIR, *ANTIVIRAL agents, *VOLTAMMETRY, *COVID-19, *DETECTION limit, *VOLTAMMETRY technique

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis

Autoren: Cheema, H. A. Abdul Rab, S. Butt, M. et al.

Quelle: Journal of Microbiology, Immunology and Infection. 57(3):396-402

Schlagwörter: COVID-19, EIDD-2801, MK-4482, Molnupiravir, SARS-CoV-2

Dateibeschreibung: electronic

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:miun:diva-51088
https://doi.org/10.1016/j.jmii.2024.03.002

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Quelle: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression

Other URLs: https://externaldatasharing-msd.com/

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration Open Access.

Autoren: Nguyen, Bach Tran Bertrand, Julie Agyeman, Akosua A et al.

Quelle: Journal of Infectious Diseases. 6/15/2025, Vol. 231 Issue 6, pe1080-e1090. 11p.

Schlagwörter: *MOLNUPIRAVIR, *VIROIDS, *VIRAL replication, *TREATMENT duration, *RNA viruses

Treatment of feline infectious peritonitis in cats with molnupiravir: clinical observations and outcomes for 54 cases.

Autoren: Clark, TM Coggins, SJ Korman, R et al.

Quelle: Australian Veterinary Journal. Jun2025, Vol. 103 Issue 6, p339-353. 15p.

Schlagwörter: *MOLNUPIRAVIR, *TREATMENT effectiveness, *ADVERSE health care events, *HEALTH outcome assessment, *ANTIVIRAL agents, *CATS, *CORONAVIRUS diseases

Benzoyl Chloride Derivatization Coupled With Liquid Chromatography‐Mass Spectrometry for the Simultaneous Quantification of Molnupiravir and Its Metabolite β‐d‐N⁴‐hydroxycytidine in Human Plasma.

Autoren: Yuan, Zhilong Ma, Tao Xia, Lin et al.

Quelle: Journal of Separation Science. May2025, Vol. 48 Issue 5, p1-9. 9p.

Schlagwörter: *MOLNUPIRAVIR, *BENZOYL chloride, *SCIENTIFIC method, *MASS spectrometry, *PHARMACOKINETICS, *LIQUID chromatography, *BLOOD plasma, *METABOLOMICS

Exploring the Molecular Level Interactions of Molnupiravir with Serum Albumin-An Analytical Approach.

Autoren: Begum, Shaheen D., Usha Rani Somanjeri, Nithya et al.

Quelle: Journal of Neonatal Surgery. 2025 Supplement, Vol. 14, p101-107. 7p.

Schlagwörter: *MOLNUPIRAVIR, *SERUM albumin, *CORONAVIRUS diseases, *THERMODYNAMICS, *QUENCHING (Chemistry), *SPECTROMETRY

Stability Indicating High Performance Liquid Chromatography Method Development, Validation, and Characterization of Forced Degradant Product by Liquid Chromatography–Mass Spectroscopy for Molnupiravir and Favipiravir.

Autoren: Pethani, Trupesh M Sangani, Monika Santoki, Param S

Quelle: Journal of Chromatographic Science. Apr2025, Vol. 63 Issue 4, p1-8. 8p.

Schlagwörter: *LIQUID chromatography-mass spectrometry, *MOLNUPIRAVIR, *CHEMICAL decomposition, *MODEL validation, *COVID-19, *HIGH performance liquid chromatography, *ANTIVIRAL agents

Firma/Körperschaft: INTERNATIONAL Conference on Harmonisation

DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR THE DETERMINATION OF RELATED SUBSTANCES IN MOLNUPIRAVIR DRUG SUBSTANCE.

Autoren: Gannamani, Kiran Kumar Chintakula, Sudhakar

Quelle: Rasayan Journal of Chemistry. Apr-Jun2025, Vol. 18 Issue 2, p1060-1071. 12p.

Schlagwörter: *MOLNUPIRAVIR, *COVID-19, *VIRAL genomes, *SARS-CoV-2 Omicron variant, *VIRAL load, *PRODRUGS, *ANTIVIRAL agents

Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19.

Autoren: Chawla, Akshita Birger, Ruthie Maas, Brian M. et al.

Quelle: CTS: Clinical & Translational Science. Apr2025, Vol. 18 Issue 4, p1-9. 9p.

Schlagwörter: *MOLNUPIRAVIR, *COVID-19, *TREATMENT effectiveness, *VIROLOGY, *GENETIC mutation, *DRUG interactions, *SARS-CoV-2, *BIOMARKERS